PL2922828T3 - Pochodne 4,6-diaminopirymidynowe jako inhibitory bmi-1 w leczeniu raka - Google Patents
Pochodne 4,6-diaminopirymidynowe jako inhibitory bmi-1 w leczeniu rakaInfo
- Publication number
- PL2922828T3 PL2922828T3 PL13857326T PL13857326T PL2922828T3 PL 2922828 T3 PL2922828 T3 PL 2922828T3 PL 13857326 T PL13857326 T PL 13857326T PL 13857326 T PL13857326 T PL 13857326T PL 2922828 T3 PL2922828 T3 PL 2922828T3
- Authority
- PL
- Poland
- Prior art keywords
- bmi
- diamino
- inhibitors
- treating cancer
- pyrimidine derivatives
- Prior art date
Links
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- MISVBCMQSJUHMH-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical class NC1=CC(N)=NC=N1 MISVBCMQSJUHMH-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hematology (AREA)
- Oncology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261728907P | 2012-11-21 | 2012-11-21 | |
| EP13857326.6A EP2922828B1 (en) | 2012-11-21 | 2013-11-21 | 4,6-diamino-pyrimidine derivatives as bmi-1 inhibitors for treating cancer |
| PCT/US2013/071132 WO2014081906A2 (en) | 2012-11-21 | 2013-11-21 | Substituted reverse pyrimidine bmi-1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2922828T3 true PL2922828T3 (pl) | 2020-12-28 |
Family
ID=50776672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13857326T PL2922828T3 (pl) | 2012-11-21 | 2013-11-21 | Pochodne 4,6-diaminopirymidynowe jako inhibitory bmi-1 w leczeniu raka |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US10428050B2 (pl) |
| EP (1) | EP2922828B1 (pl) |
| JP (3) | JP6412503B2 (pl) |
| KR (4) | KR102356487B1 (pl) |
| CN (2) | CN111423417B (pl) |
| AR (1) | AR093579A1 (pl) |
| AU (1) | AU2013348009C1 (pl) |
| BR (1) | BR112015011760B1 (pl) |
| CA (1) | CA2892045C (pl) |
| CL (1) | CL2015001377A1 (pl) |
| CR (1) | CR20150294A (pl) |
| CU (1) | CU24387B1 (pl) |
| DK (1) | DK2922828T3 (pl) |
| EA (2) | EA035349B1 (pl) |
| EC (1) | ECSP15019948A (pl) |
| ES (1) | ES2821529T3 (pl) |
| HK (1) | HK1215032A1 (pl) |
| IL (2) | IL238871B (pl) |
| MA (1) | MA38208B1 (pl) |
| MX (2) | MX385385B (pl) |
| NI (1) | NI201500072A (pl) |
| NZ (2) | NZ746607A (pl) |
| PE (1) | PE20151413A1 (pl) |
| PH (1) | PH12015501130B1 (pl) |
| PL (1) | PL2922828T3 (pl) |
| PT (1) | PT2922828T (pl) |
| SA (1) | SA517381847B1 (pl) |
| SG (2) | SG11201503982XA (pl) |
| TW (1) | TWI623531B (pl) |
| UA (1) | UA118094C2 (pl) |
| WO (1) | WO2014081906A2 (pl) |
| ZA (1) | ZA201503642B (pl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2922828B1 (en) * | 2012-11-21 | 2020-07-08 | PTC Therapeutics, Inc. | 4,6-diamino-pyrimidine derivatives as bmi-1 inhibitors for treating cancer |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| AU2014287121B2 (en) * | 2013-07-11 | 2018-11-15 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer |
| TWI692477B (zh) * | 2013-08-30 | 2020-05-01 | 美商Ｐｔｃ治療公司 | 經取代嘧啶ｂｍｉ-１抑制劑 |
| WO2015076800A1 (en) | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
| JP7001593B2 (ja) | 2015-08-11 | 2022-01-19 | コグノア， インコーポレイテッド | 人工知能およびユーザ入力を用いて発達進度を判定するための方法および装置 |
| US10851082B2 (en) | 2015-10-28 | 2020-12-01 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) |
| US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
| CA3010615C (en) * | 2016-01-14 | 2024-02-20 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
| CN118609834A (zh) | 2016-11-14 | 2024-09-06 | 科格诺亚公司 | 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置 |
| EP3580700A4 (en) * | 2017-02-09 | 2020-11-18 | Cognoa, Inc. | PLATFORM AND SYSTEM FOR DIGITAL PERSONALIZED MEDICINE |
| KR20200035292A (ko) | 2017-08-01 | 2020-04-02 | 피티씨 테라퓨틱스, 인크. | 혈액 암 치료에 사용하기 위한 dhodh 억제제 |
| EP3564235A1 (en) * | 2018-05-03 | 2019-11-06 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2) |
| US12023335B2 (en) * | 2018-08-17 | 2024-07-02 | Ptc Therapeutics, Inc. | Method for treating pancreatic cancer |
| CN109988172B (zh) * | 2019-01-10 | 2020-09-29 | 石家庄学院 | 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法 |
| BR112021013913A2 (pt) * | 2019-01-15 | 2021-09-21 | Ptc Therapeutics, Inc. | Método para tratar uma leucemia mieloide aguda |
| EA202192117A1 (ru) * | 2019-02-28 | 2021-11-23 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способ лечения множественной миеломы |
| PE20212270A1 (es) * | 2019-03-11 | 2021-11-30 | Ptc Therapeutics Inc | Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas |
| KR102785528B1 (ko) | 2019-03-22 | 2025-03-21 | 코그노아, 인크. | 개인 맞춤식 디지털 치료 방법 및 디바이스 |
| EA202192349A1 (ru) * | 2019-03-27 | 2022-02-01 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Комбинации, пригодные в способе лечения саркомы |
| WO2020200209A1 (zh) * | 2019-04-02 | 2020-10-08 | 成都海创药业有限公司 | 芳香胺类化合物及其在制备ar和brd4双重抑制剂和调控剂中的用途 |
| CN116917009A (zh) | 2021-02-19 | 2023-10-20 | 美国迈胜医疗系统有限公司 | 用于粒子治疗系统的机架 |
| US20240120050A1 (en) * | 2022-10-07 | 2024-04-11 | Insight Direct Usa, Inc. | Machine learning method for predicting a health outcome of a patient using video and audio analytics |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH593266A5 (pl) * | 1973-09-20 | 1977-11-30 | Delalande Sa | |
| JP2896532B2 (ja) | 1994-08-13 | 1999-05-31 | ユーハン コーポレーション | 新規なピリミジン誘導体およびその製造方法 |
| IN188411B (pl) | 1997-03-27 | 2002-09-21 | Yuhan Corp | |
| KR100272471B1 (ko) | 1998-11-17 | 2000-11-15 | 김선진 | 신규의 피리미딘 유도체 및 그의 제조방법 |
| GB9905075D0 (en) * | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| CA2383546A1 (en) | 1999-06-30 | 2001-01-04 | William H. Parsons | Src kinase inhibitor compounds |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| CA2386218A1 (en) | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
| DE60024480T2 (de) | 1999-10-27 | 2006-07-27 | Novartis Ag | Thiazol und imidazo[4,5-b]pyridin verbindungen und ihre verwendung als pharmazeutika |
| US20030004174A9 (en) * | 2000-02-17 | 2003-01-02 | Armistead David M. | Kinase inhibitors |
| AU4262901A (en) | 2000-03-29 | 2001-10-08 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders |
| ATE346064T1 (de) | 2000-09-15 | 2006-12-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinasehemmer |
| HK1054393B (en) | 2000-09-20 | 2009-08-28 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazine derivatives as modulators of tyrosine kinases |
| AU2002228922A1 (en) * | 2000-12-12 | 2002-06-24 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| US6716851B2 (en) * | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
| US7163940B2 (en) | 2000-12-15 | 2007-01-16 | Smithkline Beecham Corporation | Pyrazolopyridinyl pyrimidine therapeutic compounds |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| ES2316546T3 (es) | 2001-02-20 | 2009-04-16 | Astrazeneca Ab | 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3. |
| ATE497603T1 (de) | 2001-03-02 | 2011-02-15 | Gpc Biotech Ag | Drei-hybrid-assaysystem |
| US7196095B2 (en) | 2001-06-25 | 2007-03-27 | Merck & Co., Inc. | (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds |
| JP4342937B2 (ja) | 2001-07-03 | 2009-10-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | ＳｒｃおよびＬｃｋタンパク質キナーゼの阻害剤としてのイソキサゾールピリミジン |
| US7109204B2 (en) | 2001-08-01 | 2006-09-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2003075828A2 (en) * | 2002-03-11 | 2003-09-18 | Zetiq Technologies Ltd. | Compounds useful in the treatment of cancer |
| US7259179B2 (en) | 2002-05-23 | 2007-08-21 | Cytopia Research Pty Ltd | Kinase inhibitors |
| US7494997B2 (en) | 2002-06-28 | 2009-02-24 | Nippon Shinyaku Co., Ltd. | Amide derivative |
| GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| WO2004007407A2 (en) * | 2002-07-11 | 2004-01-22 | Fluorous Technologies Incorporated | Fluorous tagging and scavenging reactants and methods of synthesis and use thereof |
| US20040110821A1 (en) * | 2002-08-07 | 2004-06-10 | Konkel Michael J. | GAL3 receptor antagonists for the treatment of affective disorders |
| UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| JP2006504755A (ja) | 2002-10-15 | 2006-02-09 | スミスクライン ビーチャム コーポレーション | Ｇｓｋ−３阻害薬としてのピリダジン化合物 |
| US7169781B2 (en) | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
| KR101164541B1 (ko) | 2004-01-12 | 2012-07-10 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 선택적 키나제 저해제 |
| WO2005076854A2 (en) | 2004-02-04 | 2005-08-25 | Smithkline Beecham Corporation | Pyrimidinone compounds useful as kinase inhibitors |
| PT1730146E (pt) * | 2004-03-30 | 2011-07-11 | Vertex Pharma | Azaindoles úteis como inibidores de jak e outras proteínas quinases |
| JP2006045119A (ja) | 2004-08-04 | 2006-02-16 | Toray Ind Inc | ピラジン誘導体及びそれを有効成分とする腎炎治療薬 |
| WO2006050076A1 (en) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| AU2006219231B2 (en) | 2005-02-28 | 2010-01-14 | Japan Tobacco Inc. | Novel aminopyridine compound with Syk inhibitory activity |
| GT200600105A (es) | 2005-03-10 | 2007-02-14 | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos. | |
| BRPI0713328A2 (pt) | 2006-06-22 | 2012-10-30 | Biovitrum Ab | derivados de piridina e pirazina como inibidores de cinase mnk |
| CA2665398A1 (en) | 2006-10-03 | 2008-04-10 | Neurosearch A/S | Indazolyl derivatives useful as potassium channel modulating agents |
| CN101516873A (zh) | 2006-10-03 | 2009-08-26 | 神经研究公司 | 用作钾通道调节剂的吲唑基衍生物 |
| ZA200902384B (en) | 2006-10-19 | 2010-07-28 | Signal Pharm Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
| AU2007336933A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections |
| AR065015A1 (es) | 2007-01-26 | 2009-05-13 | Smithkline Beecham Corp | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| WO2008132502A1 (en) | 2007-04-25 | 2008-11-06 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer |
| GB0714573D0 (en) | 2007-07-26 | 2007-09-05 | Imp Innovations Ltd | Marker gene |
| WO2009037247A1 (en) | 2007-09-17 | 2009-03-26 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
| WO2009064835A1 (en) | 2007-11-16 | 2009-05-22 | Incyte Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
| CA2707989A1 (en) | 2007-12-07 | 2009-06-11 | Novartis Ag | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
| DE102008005493A1 (de) | 2008-01-22 | 2009-07-23 | Merck Patent Gmbh | 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate |
| GB0801416D0 (en) | 2008-01-25 | 2008-03-05 | Piramed Ltd | Pharmaceutical compounds |
| NZ588830A (en) | 2008-04-22 | 2012-11-30 | Portola Pharm Inc | Inhibitors of protein kinases |
| EP2306836B1 (en) * | 2008-07-01 | 2016-09-07 | PTC Therapeutics, Inc. | Bmi-1 protein expression modulators |
| ATE542813T1 (de) | 2008-08-06 | 2012-02-15 | Pfizer | 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren |
| CN102177154A (zh) * | 2008-09-02 | 2011-09-07 | 神经研究公司 | 吡唑基-嘧啶衍生物及其作为钾通道调节剂的应用 |
| WO2010061903A1 (ja) * | 2008-11-27 | 2010-06-03 | 塩野義製薬株式会社 | Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体 |
| AU2010214440A1 (en) | 2009-02-12 | 2011-09-01 | Astellas Pharma Inc. | Hetero ring derivative |
| NZ595372A (en) | 2009-03-27 | 2013-11-29 | Vetdc Inc | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| ES2453097T3 (es) | 2009-05-27 | 2014-04-04 | Abbvie Inc. | Inhibidores de pirimidina de actividad quinasa |
| WO2010144416A1 (en) | 2009-06-08 | 2010-12-16 | Gaeta Federico C A | SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY |
| PH12015501678B1 (en) * | 2009-06-17 | 2022-07-06 | Vertex Pharma | Inhibitors of influenza viruses replication |
| EP2451802A1 (en) | 2009-07-07 | 2012-05-16 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| JP2012533551A (ja) | 2009-07-15 | 2012-12-27 | アボット・ラボラトリーズ | ピロロピラジン系キナーゼ阻害薬 |
| JP2012533553A (ja) | 2009-07-15 | 2012-12-27 | アボット・ラボラトリーズ | ピロロピリジン系キナーゼ阻害薬 |
| JP2011136925A (ja) | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | 含窒素二環性化合物 |
| EA022188B1 (ru) | 2010-01-12 | 2015-11-30 | Аб Сьянс | Оксазольные ингибиторы киназы, содержащие их композиции и их применение |
| UY33213A (es) * | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| ES2365960B1 (es) * | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| KR101788903B1 (ko) * | 2010-08-19 | 2017-10-23 | 에프. 호프만-라 로슈 아게 | 체세포의 유도된 재프로그래밍된 신경 줄기 세포 (ｉｒｎｓｃｓ) 로의 전환 |
| EA026132B1 (ru) | 2010-09-13 | 2017-03-31 | Новартис Аг | Триазиноксадиазолы, фармацевтические композиции на их основе и их применение |
| WO2012050884A2 (en) * | 2010-09-28 | 2012-04-19 | President And Fellows Of Harvard College | Cardiac glycosides are potent inhibitors of interferon-beta gene expression |
| CA2819373A1 (en) | 2010-12-09 | 2012-06-14 | Amgen Inc. | Bicyclic compounds as pim inhibitors |
| PL2678332T3 (pl) | 2011-02-25 | 2016-12-30 | Pochodne diaminopirymidyny i sposoby ich wytwarzania | |
| US9199962B2 (en) * | 2011-07-07 | 2015-12-01 | Merck Patent Gmbh | Substituted azaheterocycles for the treatment of cancer |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| EP2922828B1 (en) * | 2012-11-21 | 2020-07-08 | PTC Therapeutics, Inc. | 4,6-diamino-pyrimidine derivatives as bmi-1 inhibitors for treating cancer |
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| PE20212270A1 (es) * | 2019-03-11 | 2021-11-30 | Ptc Therapeutics Inc | Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas |
-
2013
- 2013-11-21 EP EP13857326.6A patent/EP2922828B1/en active Active
- 2013-11-21 PT PT138573266T patent/PT2922828T/pt unknown
- 2013-11-21 EA EA201890142A patent/EA035349B1/ru not_active IP Right Cessation
- 2013-11-21 BR BR112015011760-0A patent/BR112015011760B1/pt active IP Right Grant
- 2013-11-21 JP JP2015544124A patent/JP6412503B2/ja active Active
- 2013-11-21 PE PE2015000665A patent/PE20151413A1/es unknown
- 2013-11-21 WO PCT/US2013/071132 patent/WO2014081906A2/en not_active Ceased
- 2013-11-21 TW TW102142555A patent/TWI623531B/zh active
- 2013-11-21 CU CU2015000053A patent/CU24387B1/es unknown
- 2013-11-21 EA EA201590992A patent/EA031405B1/ru unknown
- 2013-11-21 PL PL13857326T patent/PL2922828T3/pl unknown
- 2013-11-21 MX MX2015006469A patent/MX385385B/es unknown
- 2013-11-21 US US14/443,911 patent/US10428050B2/en active Active
- 2013-11-21 AU AU2013348009A patent/AU2013348009C1/en active Active
- 2013-11-21 CN CN202010080540.0A patent/CN111423417B/zh active Active
- 2013-11-21 KR KR1020217020963A patent/KR102356487B1/ko active Active
- 2013-11-21 SG SG11201503982XA patent/SG11201503982XA/en unknown
- 2013-11-21 CA CA2892045A patent/CA2892045C/en active Active
- 2013-11-21 NZ NZ74660713A patent/NZ746607A/en unknown
- 2013-11-21 NZ NZ70890913A patent/NZ708909A/en unknown
- 2013-11-21 DK DK13857326.6T patent/DK2922828T3/da active
- 2013-11-21 SG SG10201600149VA patent/SG10201600149VA/en unknown
- 2013-11-21 CN CN201380070973.6A patent/CN104918919A/zh active Pending
- 2013-11-21 KR KR1020227035587A patent/KR20220143164A/ko not_active Ceased
- 2013-11-21 MA MA38208A patent/MA38208B1/fr unknown
- 2013-11-21 KR KR1020227002513A patent/KR102455889B1/ko active Active
- 2013-11-21 AR ARP130104300A patent/AR093579A1/es active IP Right Grant
- 2013-11-21 UA UAA201505533A patent/UA118094C2/uk unknown
- 2013-11-21 PH PH1/2015/501130A patent/PH12015501130B1/en unknown
- 2013-11-21 HK HK16103069.2A patent/HK1215032A1/zh unknown
- 2013-11-21 KR KR1020157016184A patent/KR102275676B1/ko active Active
- 2013-11-21 ES ES13857326T patent/ES2821529T3/es active Active
-
2015
- 2015-05-18 IL IL238871A patent/IL238871B/en active IP Right Grant
- 2015-05-20 CL CL2015001377A patent/CL2015001377A1/es unknown
- 2015-05-21 SA SA517381847A patent/SA517381847B1/ar unknown
- 2015-05-21 MX MX2021009892A patent/MX2021009892A/es unknown
- 2015-05-21 NI NI201500072A patent/NI201500072A/es unknown
- 2015-05-21 EC ECIEPI201519948A patent/ECSP15019948A/es unknown
- 2015-05-22 ZA ZA2015/03642A patent/ZA201503642B/en unknown
- 2015-06-05 CR CR20150294A patent/CR20150294A/es unknown
-
2018
- 2018-09-28 JP JP2018183173A patent/JP6617186B2/ja active Active
-
2019
- 2019-03-10 IL IL265253A patent/IL265253A/en unknown
- 2019-09-26 US US16/583,442 patent/US11180483B2/en not_active Expired - Fee Related
- 2019-11-11 JP JP2019203706A patent/JP6918898B2/ja active Active
-
2021
- 2021-11-10 US US17/523,480 patent/US20220064150A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2922828T3 (pl) | Pochodne 4,6-diaminopirymidynowe jako inhibitory bmi-1 w leczeniu raka | |
| IL242284A (en) | Annals 2– (2, 4, 5 – Inilino – Converted) as egfr modulators for cancer treatment | |
| IL245062B (en) | History of 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-h4-pyrido[3,2-b]pyrazine-8 -Il)oxy]phenyl]urea as raf inhibitors for cancer treatment | |
| IL238942B (en) | History of pyrimidine-4,2-diamine for cancer treatment | |
| PL3967315T3 (pl) | Akkermansia muciniphila do leczenia nowotworu złośliwego | |
| EP2721033A4 (en) | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS IDH1 MUTANT INHIBITORS FOR THE TREATMENT OF CANCER | |
| ZA201409256B (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
| ZA201406777B (en) | 3,5-diaminopyrazole kinase inhibitors | |
| IL235681A (en) | 5-amino [1, 4] thiazines as 1bace inhibitors | |
| ZA201503005B (en) | Ingenol-derived compounds useful for treating cancer | |
| PL2817286T3 (pl) | Inhibitory kinazy do leczenia raka | |
| WO2013025939A9 (en) | Compounds and methods for treating cancer by inhibiting the urokinase receptor | |
| IL225520A0 (en) | History of 4-(methylaminophenoxy)pyridin-3-yl-benzamide for cancer treatment | |
| AU2012901918A0 (en) | Methods for treating cancer | |
| AU2012901199A0 (en) | Kinase inhibitors for the Treatment of Cancer | |
| PT2925744T (pt) | Derivados de pirimidina-2,4-diamina para tratamento de cancro | |
| HUE048942T2 (hu) | Antraciklin-származékok tumorbetegségek kezeléséhez |